Your browser is no longer supported. Please, upgrade your browser.
Settings
ATRC AtriCure, Inc. daily Stock Chart
ATRC [NASD]
AtriCure, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own2.50% Shs Outstand44.01M Perf Week2.33%
Market Cap1.96B Forward P/E- EPS next Y-0.83 Insider Trans-2.16% Shs Float43.45M Perf Month20.08%
Income-45.70M PEG- EPS next Q-0.28 Inst Own96.50% Short Float4.33% Perf Quarter3.10%
Sales210.10M P/S9.35 EPS this Y-43.20% Inst Trans1.21% Short Ratio5.01 Perf Half Y-6.60%
Book/sh9.49 P/B4.62 EPS next Y17.80% ROA-7.30% Target Price54.38 Perf Year46.48%
Cash/sh5.20 P/C8.43 EPS next 5Y20.00% ROE-14.00% 52W Range23.17 - 51.76 Perf YTD34.85%
Dividend- P/FCF- EPS past 5Y-8.80% ROI-10.40% 52W High-15.30% Beta1.06
Dividend %- Quick Ratio5.90 Sales past 5Y16.50% Gross Margin72.20% 52W Low89.25% ATR1.64
Employees730 Current Ratio6.60 Sales Q/Q-3.20% Oper. Margin-20.00% RSI (14)70.76 Volatility3.20% 4.71%
OptionableYes Debt/Eq0.15 EPS Q/Q54.50% Profit Margin-21.70% Rel Volume0.49 Prev Close43.63
ShortableYes LT Debt/Eq0.15 EarningsNov 05 AMC Payout- Avg Volume375.39K Price43.84
Recom1.40 SMA2011.72% SMA5011.68% SMA2007.26% Volume184,538 Change0.48%
Nov-06-20Reiterated Needham Buy $63 → $53
Apr-07-20Initiated Oppenheimer Outperform $45
Feb-06-20Initiated BTIG Research Buy $42
Jan-24-20Reiterated Needham Buy $39 → $48
Aug-13-19Downgrade Northland Capital Outperform → Market Perform $30
Apr-12-19Initiated JP Morgan Overweight $37
Oct-04-18Reiterated Needham Buy $36 → $39
Aug-02-18Reiterated Stifel Buy $32 → $34
Aug-02-18Reiterated Needham Buy $32 → $36
Jun-18-18Reiterated Needham Buy $26 → $32
Apr-27-18Reiterated Needham Buy $23 → $26
Jan-16-18Reiterated Needham Buy $25 → $23
Nov-02-17Reiterated Needham Buy $26 → $25
Jul-28-17Reiterated Needham Buy $25 → $26
May-30-17Resumed Piper Jaffray Overweight
Jun-30-16Resumed JMP Securities Mkt Outperform
Oct-28-15Reiterated Needham Buy $30 → $23
Oct-06-15Reiterated Needham Buy $32 → $30
Oct-06-15Reiterated Canaccord Genuity Buy $31 → $28
Aug-04-15Reiterated Needham Buy $29 → $32
Nov-19-20 11:44AM  
08:00AM  
Nov-06-20 09:30AM  
Nov-05-20 06:25PM  
04:01PM  
02:30PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-13-20 08:00AM  
Oct-06-20 05:41PM  
Sep-28-20 06:39AM  
Sep-01-20 08:00AM  
Aug-06-20 04:00PM  
Aug-03-20 08:55AM  
Jul-30-20 06:39AM  
Jul-29-20 08:00AM  
05:01AM  
Jul-28-20 04:22PM  
04:01PM  
Jul-21-20 12:31PM  
Jul-07-20 08:00AM  
Jun-19-20 12:45PM  
Jun-17-20 04:53AM  
May-11-20 08:10PM  
07:16AM  
May-08-20 08:47AM  
Apr-30-20 11:00AM  
08:30AM  
Apr-29-20 05:25PM  
04:01PM  
Apr-27-20 04:02PM  
Apr-22-20 12:31PM  
Apr-15-20 08:00AM  
Apr-14-20 06:42AM  
Apr-13-20 08:00AM  
Apr-09-20 12:26PM  
08:00AM  
Apr-06-20 04:14PM  
Apr-01-20 03:00PM  
Mar-24-20 05:09PM  
Mar-23-20 02:29PM  
Mar-12-20 09:21AM  
Feb-28-20 02:53PM  
Feb-25-20 10:37PM  
Feb-20-20 05:54AM  
Feb-18-20 04:01PM  
02:30PM  
Feb-03-20 08:00AM  
Jan-31-20 07:33AM  
Jan-28-20 11:15AM  
08:00AM  
Jan-10-20 08:14AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-10-19 11:28AM  
Dec-09-19 01:12PM  
Dec-05-19 06:13AM  
Dec-04-19 08:00AM  
Dec-02-19 09:33AM  
Nov-12-19 08:00AM  
Nov-06-19 02:22PM  
Oct-30-19 06:15PM  
04:02PM  
Oct-27-19 02:02PM  
Oct-23-19 10:33AM  
Oct-21-19 08:00AM  
Oct-09-19 06:18PM  
Oct-08-19 11:06AM  
08:00AM  
Sep-02-19 03:18PM  
Aug-28-19 10:50AM  
Aug-27-19 08:00AM  
Aug-26-19 08:00AM  
Aug-14-19 02:26PM  
Aug-13-19 02:16PM  
Aug-12-19 11:04AM  
05:30AM  
Jul-31-19 02:39PM  
08:24AM  
Jul-30-19 06:35PM  
04:02PM  
02:30PM  
Jul-26-19 02:09PM  
Jul-23-19 10:32AM  
Jul-17-19 04:00PM  
Jul-12-19 10:15AM  
Jul-10-19 08:00AM  
Jul-06-19 07:00AM  
Jun-14-19 09:09AM  
May-24-19 01:34PM  
May-05-19 03:53PM  
May-02-19 02:58PM  
May-01-19 07:46PM  
Apr-26-19 07:28AM  
Apr-25-19 05:05PM  
04:01PM  
02:30PM  
Apr-23-19 08:00AM  
Apr-18-19 10:33AM  
Apr-04-19 08:00AM  
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Drake Scott WilliamDirectorNov 17Buy40.5412,350500,66941,036Nov 19 07:40 AM
Seith Douglas JChief Operating OfficerOct 09Sale40.0929,1611,169,064129,497Oct 13 08:23 AM
Collar Mark ADirectorOct 06Sale40.002,33093,20078,558Oct 08 08:39 AM
Collar Mark ADirectorOct 01Sale40.2067026,93480,888Oct 05 08:45 AM
GROVES REGINA EDirectorSep 14Sale41.836,313264,07321,809Sep 16 04:12 PM
Collar Mark ADirectorJul 01Sale44.604,000178,40081,558Jul 06 08:21 AM
Collar Mark ADirectorMay 12Option Exercise5.1510,00051,50083,106May 14 08:12 AM
CARREL MICHAEL HPresident, CEO, & DirectorMay 12Option Exercise5.9125,000147,750539,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 12Sale47.0025,0001,175,000514,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 11Option Exercise5.9125,000147,750539,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 11Sale46.0025,0001,150,000514,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 08Option Exercise5.9125,000147,750539,147May 08 05:02 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 08Sale45.0025,0001,125,000514,147May 08 05:02 PM
Lanning Mark RDirectorApr 27Option Exercise5.1510,00051,500128,434Apr 29 08:03 AM
Noznesky Justin JSVP, Mktg & Business DevelopApr 17Sale40.0010,000400,00051,255Apr 20 08:01 AM
Collar Mark ADirectorApr 07Sale36.074,000144,28073,106Apr 09 08:09 AM
Noznesky Justin JSVP, Mktg & Business DevelopApr 07Sale35.0010,000350,00061,255Apr 09 08:05 AM
Wade M. AndrewCFOFeb 21Option Exercise6.5845,000295,950160,120Feb 24 08:14 AM
Wade M. AndrewCFOFeb 21Sale39.4545,0001,775,400145,120Feb 24 08:14 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 14Option Exercise5.9125,000147,750651,490Feb 18 08:07 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 14Sale44.0025,0001,100,000626,490Feb 18 08:07 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 13Option Exercise5.9125,000147,750651,490Feb 14 08:40 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 13Sale43.0025,0001,075,000626,490Feb 14 08:40 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 11Option Exercise5.9125,000147,750651,490Feb 12 08:08 AM
Seith Douglas JChief Operating OfficerFeb 11Option Exercise21.0450,0001,052,000201,299Feb 13 08:07 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 11Sale42.0025,0001,050,000626,490Feb 12 08:08 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 10Option Exercise5.9125,000147,750651,490Feb 12 08:08 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 10Sale41.0025,0001,025,000626,490Feb 12 08:08 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 29Option Exercise5.9125,000147,750651,490Jan 31 07:35 AM
Seith Douglas JChief Operating OfficerJan 29Option Exercise6.7337,000249,010169,682Jan 31 07:32 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 29Sale40.0025,0001,000,000626,490Jan 31 07:35 AM
Seith Douglas JChief Operating OfficerJan 17Option Exercise6.7338,000255,740147,772Jan 21 08:47 AM
Wade M. AndrewSVP and CFOJan 16Option Exercise6.2710,00062,700155,120Jan 17 07:41 AM
Wade M. AndrewSVP and CFOJan 16Sale36.0010,000360,000145,120Jan 17 07:41 AM
Seith Douglas JChief Operating OfficerJan 16Sale36.0025,471916,956106,272Jan 17 07:44 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 15Option Exercise5.9125,000147,750651,490Jan 16 07:22 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 15Sale35.0025,000875,000626,490Jan 16 07:22 AM
Collar Mark ADirectorJan 15Sale35.024,000140,08077,106Jan 17 07:38 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 14Option Exercise5.9125,000147,750651,490Jan 16 07:22 AM
Wade M. AndrewSVP and CFOJan 14Option Exercise6.2710,00062,700155,120Jan 16 07:55 AM
Wade M. AndrewSVP and CFOJan 14Sale34.0010,000340,000145,120Jan 16 07:55 AM
Seith Douglas JChief Operating OfficerJan 14Sale34.0036,3631,236,342131,743Jan 16 07:31 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 14Sale34.0025,000850,000626,490Jan 16 07:22 AM
Noznesky Justin JSVP, Mktg & Business DevelopJan 02Option Exercise18.3015,000274,500106,568Jan 06 07:34 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 02Option Exercise5.9123,546139,157650,036Jan 06 07:36 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 02Sale33.0023,546777,018626,490Jan 06 07:36 AM
Noznesky Justin JSVP, Mktg & Business DevelopJan 02Sale32.8929,134958,21777,434Jan 06 07:34 AM
Wade M. AndrewSVP and CFODec 26Option Exercise11.201,00011,200145,715Dec 30 07:49 AM
Seith Douglas JChief Operating OfficerDec 26Sale32.0031,4401,006,080168,106Dec 30 07:46 AM
Wade M. AndrewSVP and CFODec 26Sale32.001,00032,000144,715Dec 30 07:49 AM
CDXS Codexis, Inc. daily Stock Chart
CDXS [NASD]
Codexis, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own1.10% Shs Outstand59.06M Perf Week9.42%
Market Cap1.06B Forward P/E- EPS next Y-0.41 Insider Trans-11.44% Shs Float57.32M Perf Month32.72%
Income-20.70M PEG- EPS next Q-0.12 Inst Own91.70% Short Float8.33% Perf Quarter30.51%
Sales66.70M P/S15.87 EPS this Y-1.30% Inst Trans0.47% Short Ratio15.78 Perf Half Y45.83%
Book/sh1.54 P/B11.69 EPS next Y10.90% ROA-14.30% Target Price19.33 Perf Year14.49%
Cash/sh1.22 P/C14.81 EPS next 5Y15.00% ROE-21.20% 52W Range8.43 - 18.87 Perf YTD12.63%
Dividend- P/FCF- EPS past 5Y15.80% ROI-11.90% 52W High-4.56% Beta1.08
Dividend %- Quick Ratio5.00 Sales past 5Y14.20% Gross Margin83.10% 52W Low113.64% ATR0.62
Employees161 Current Ratio5.00 Sales Q/Q-16.00% Oper. Margin-31.20% RSI (14)80.62 Volatility4.08% 4.34%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-31.10% Rel Volume0.59 Prev Close17.86
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume302.50K Price18.01
Recom1.70 SMA2016.54% SMA5028.56% SMA20045.79% Volume179,631 Change0.84%
Mar-10-20Initiated The Benchmark Company Buy
Jan-17-19Upgrade First Analysis Sec Neutral → Outperform $12 → $19
May-16-18Initiated Stephens Overweight $16
Oct-13-17Reiterated H.C. Wainwright Buy $8 → $8.50
May-31-17Initiated Jefferies Buy $8
Jan-26-17Downgrade First Analysis Sec Overweight → Equal-Weight $5.50
Jan-04-17Upgrade Ladenburg Thalmann Neutral → Buy
Jan-06-16Initiated H.C. Wainwright Buy $6
Nov-24-20 05:02PM  
Nov-09-20 07:00AM  
Nov-07-20 08:38AM  
Nov-05-20 08:30PM  
04:05PM  
02:45PM  
Oct-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-11-20 08:33AM  
Aug-06-20 04:05PM  
07:00AM  
Jul-30-20 07:00AM  
Jul-28-20 12:33PM  
Jun-23-20 07:00AM  
Jun-22-20 03:06PM  
Jun-16-20 04:05PM  
Jun-14-20 03:50PM  
Jun-01-20 04:05PM  
May-27-20 07:00AM  
May-22-20 07:31PM  
May-11-20 07:00AM  
06:51AM  
May-09-20 01:30AM  
May-07-20 04:05PM  
May-06-20 04:05PM  
May-05-20 07:00AM  
Apr-30-20 07:00AM  
Apr-27-20 12:31PM  
Apr-07-20 08:37AM  
Mar-23-20 07:00AM  
Mar-13-20 01:57PM  
Mar-02-20 10:15AM  
Mar-01-20 07:19AM  
Feb-27-20 06:55PM  
04:05PM  
Feb-25-20 07:00AM  
Feb-20-20 07:00AM  
Jan-31-20 07:52AM  
Jan-13-20 04:05PM  
Jan-10-20 07:00AM  
Jan-01-20 09:06AM  
Dec-24-19 07:24AM  
Dec-23-19 07:00AM  
Dec-16-19 06:10AM  
Dec-05-19 04:05PM  
Dec-02-19 12:32PM  
Nov-16-19 09:39PM  
Nov-06-19 09:00AM  
Nov-05-19 07:55PM  
04:05PM  
07:00AM  
Oct-29-19 07:00AM  
Oct-27-19 08:13PM  
Oct-26-19 09:13AM  
Oct-15-19 04:05PM  
Sep-26-19 08:00AM  
07:00AM  
Sep-20-19 06:57AM  
Aug-29-19 07:11AM  
Aug-22-19 11:15PM  
Aug-09-19 01:32PM  
Aug-07-19 03:49PM  
08:25AM  
Aug-06-19 07:35PM  
04:06PM  
Jul-30-19 07:00AM  
Jun-27-19 03:01PM  
Jun-20-19 07:00AM  
Jun-10-19 12:06PM  
May-30-19 07:00AM  
May-16-19 09:34AM  
May-15-19 09:00AM  
May-14-19 04:05PM  
May-10-19 01:51AM  
May-09-19 10:07AM  
May-07-19 10:57AM  
03:23AM  
May-06-19 07:25PM  
06:19PM  
04:06PM  
Apr-30-19 10:54AM  
07:00AM  
Apr-29-19 07:00AM  
Apr-19-19 02:09PM  
Apr-05-19 04:05PM  
Mar-22-19 09:41AM  
Mar-14-19 11:15AM  
Mar-07-19 01:25PM  
Mar-05-19 07:00AM  
Mar-02-19 11:48AM  
Mar-01-19 07:45AM  
06:57AM  
Feb-27-19 10:18AM  
Feb-26-19 08:14PM  
04:05PM  
Feb-25-19 07:00AM  
Feb-23-19 09:13AM  
Feb-19-19 07:00AM  
Feb-14-19 07:00AM  
Feb-06-19 07:00AM  
Codexis, Inc. discovers, develops, and sells protein catalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KELLEY BERNARD JDirectorOct 21Sale14.002,50035,007211,136Oct 23 04:04 PM
Dorgan Byron LDirectorOct 09Option Exercise10.6325,000265,750187,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 09Sale13.5425,000338,528162,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 08Option Exercise10.6325,000265,750187,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 08Sale13.4925,000337,315162,790Oct 13 04:04 PM
WOLF DENNIS PDirectorSep 24Sale11.6810,000116,84561,129Sep 28 04:03 PM
KELLEY BERNARD JDirectorJul 21Sale12.792,50031,965213,636Jul 23 04:16 PM
WOLF DENNIS PDirectorJun 25Sale10.9710,000109,69471,129Jun 26 04:18 PM
BARUCH THOMAS RDirectorJun 12Sale10.614,94752,46433,093Jun 16 04:03 PM
KELLEY BERNARD JDirectorApr 21Sale10.582,50026,450207,184Apr 23 04:07 PM
BARUCH THOMAS RDirectorApr 02Sale10.527,50078,86638,040Apr 03 04:07 PM
BARUCH THOMAS RDirectorApr 01Sale10.887,50081,57645,540Apr 03 04:07 PM
WOLF DENNIS PDirectorMar 25Sale10.3810,000103,78572,177Mar 27 04:42 PM
Dorgan Byron LDirectorFeb 21Sale14.0216,702234,192153,838Feb 25 06:02 PM
KELLEY BERNARD JDirectorJan 21Sale18.002,50045,000209,684Jan 22 05:20 PM
BARUCH THOMAS RDirectorJan 16Sale18.6110,000186,09053,040Jan 17 04:18 PM
BARUCH THOMAS RDirectorJan 15Sale18.6810,000186,81663,040Jan 17 04:18 PM
WOLF DENNIS PDirectorDec 19Option Exercise3.6220,00072,400102,177Dec 20 05:07 PM
WOLF DENNIS PDirectorDec 19Sale16.2220,000324,38482,177Dec 20 05:07 PM
Dorgan Byron LDirectorDec 12Sale15.6425,000390,973170,540Dec 13 04:10 PM
BARUCH THOMAS RDirectorDec 11Sale15.5917,500272,89273,040Dec 12 04:10 PM
BARUCH THOMAS RDirectorDec 10Sale15.6117,500273,23690,540Dec 12 04:10 PM
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.83 Insider Own4.10% Shs Outstand78.50M Perf Week3.52%
Market Cap10.71B Forward P/E- EPS next Y-4.94 Insider Trans-4.22% Shs Float75.12M Perf Month-0.84%
Income-600.50M PEG- EPS next Q-1.81 Inst Own92.60% Short Float11.01% Perf Quarter-5.64%
Sales495.10M P/S21.63 EPS this Y-77.80% Inst Trans-2.53% Short Ratio12.06 Perf Half Y-7.08%
Book/sh11.36 P/B12.25 EPS next Y24.50% ROA-23.00% Target Price189.68 Perf Year25.45%
Cash/sh23.59 P/C5.90 EPS next 5Y- ROE-61.60% 52W Range78.06 - 175.00 Perf YTD7.83%
Dividend- P/FCF225.96 EPS past 5Y-23.40% ROI-47.10% 52W High-20.49% Beta1.93
Dividend %- Quick Ratio5.60 Sales past 5Y108.10% Gross Margin88.60% 52W Low78.26% ATR5.73
Employees743 Current Ratio6.10 Sales Q/Q45.40% Oper. Margin- RSI (14)52.69 Volatility3.26% 5.01%
OptionableYes Debt/Eq0.79 EPS Q/Q-47.00% Profit Margin- Rel Volume0.28 Prev Close135.72
ShortableYes LT Debt/Eq0.79 EarningsNov 05 AMC Payout- Avg Volume685.97K Price139.15
Recom1.80 SMA201.91% SMA50-0.30% SMA2001.71% Volume194,776 Change2.53%
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
Nov-25-20 08:30AM  
Nov-20-20 08:30AM  
Nov-09-20 09:30AM  
Nov-06-20 02:27PM  
12:01PM  
10:51AM  
Nov-05-20 04:59PM  
04:05PM  
04:02PM  
02:45PM  
Nov-02-20 04:30PM  
Oct-30-20 07:16PM  
Oct-29-20 02:25PM  
12:35PM  
08:36AM  
Oct-23-20 12:56PM  
Oct-22-20 07:30AM  
Oct-01-20 04:43PM  
02:56PM  
Sep-30-20 06:15PM  
Sep-28-20 05:06PM  
08:55AM  
08:55AM  
Sep-16-20 10:29AM  
Sep-15-20 08:30AM  
Sep-14-20 08:30AM  
Sep-10-20 04:32PM  
10:19AM  
07:38AM  
07:20AM  
Sep-09-20 05:19PM  
Sep-08-20 11:58PM  
03:40PM  
Sep-04-20 11:31AM  
Sep-03-20 04:30PM  
Aug-31-20 06:30PM  
Aug-26-20 10:44PM  
11:36AM  
Aug-25-20 04:45PM  
04:45PM  
08:45AM  
Aug-11-20 10:19AM  
08:30AM  
Aug-06-20 10:54AM  
Aug-05-20 06:05PM  
04:05PM  
Jul-31-20 06:15PM  
Jul-29-20 12:33PM  
08:30AM  
Jul-24-20 01:59PM  
08:30AM  
Jul-15-20 08:30AM  
Jul-10-20 08:47PM  
Jul-02-20 08:21AM  
07:00AM  
Jun-30-20 06:15PM  
08:30AM  
Jun-29-20 10:06AM  
Jun-26-20 08:30AM  
Jun-23-20 04:05PM  
10:27AM  
05:43AM  
Jun-22-20 08:00AM  
Jun-18-20 08:30AM  
Jun-16-20 12:00PM  
11:30AM  
Jun-15-20 04:02PM  
11:00AM  
Jun-09-20 10:34AM  
08:59AM  
Jun-08-20 04:15PM  
09:47AM  
08:55AM  
Jun-05-20 04:05PM  
11:31AM  
Jun-02-20 08:57PM  
05:00PM  
May-29-20 06:28PM  
01:50AM  
May-28-20 11:30AM  
May-18-20 11:38AM  
10:49AM  
May-15-20 04:15PM  
03:37PM  
10:03AM  
May-14-20 10:53AM  
May-13-20 02:56PM  
May-12-20 04:30PM  
07:52AM  
May-11-20 07:00AM  
May-07-20 11:41AM  
07:31AM  
07:19AM  
May-06-20 06:15PM  
04:05PM  
Apr-30-20 06:52PM  
Apr-29-20 08:30AM  
06:15AM  
Apr-28-20 08:30AM  
Apr-15-20 08:34AM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Option Exercise28.88125,0003,610,443155,179Dec 17 08:00 PM
Howton David TEVP, General CounselDec 13Option Exercise21.4878,0001,675,439103,171Dec 17 08:01 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Option Exercise23.7032,706775,23243,867Dec 17 08:02 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Sale125.5042,0005,271,0001,867Dec 17 08:02 PM
Howton David TEVP, General CounselDec 13Sale125.5078,0009,789,00025,171Dec 17 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Sale125.50125,00015,687,50030,179Dec 17 08:00 PM